New fibrinolytic agents for MI: As effective as current agents, but easier to administer
Keith Ellis, MD
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation
Sorin Brener, MD
Director, Angiography Core Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation
Address: Sorin Brener, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail email@example.com
ABSTRACTThe efficacy and safety of fibrinolytic agents have not dramatically changed since alteplase (Activase), a derivative of tissue plasminogen activator (t-PA), was introduced nearly 2 decades ago. However, newer agents have a longer half-life, making them easier to deliver. Fibrinolytic therapy is underused in many patients, especially in those traditionally thought to be at high risk for complications.